NewEdge Advisors’s Gain Therapeutics GANX Stock Holding History

NewEdge Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.6K	Hold	10,600	–	–	﹤0.01%	3189
2025 Q4	$34.1K	Hold	10,600	–	–	﹤0.01%	3079
2025 Q3	$18.8K	Hold	10,600	–	–	﹤0.01%	3145
2025 Q2	$19.1K	Hold	10,600	–	–	﹤0.01%	2976
2025 Q1	$20.2K	Buy	+10,600	New	+$23.5K	﹤0.01%	2860
2024 Q2	–	Sell	-225	Closed	-$848	–	3877
2024 Q1	$848	Buy	+225	New	+$933	﹤0.01%	3529
2023 Q4	–	Sell	-11,050	Closed	-$36.2K	–	3795
2023 Q3	$36.2K	Hold	11,050	–	–	﹤0.01%	2193
2023 Q2	$49.5K	Buy	11,050 +550	+5%	+$2.69K	﹤0.01%	2089
2023 Q1	$54.1K	Buy	+10,500	New	+$42.9K	﹤0.01%	1967

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

NewEdge Advisors's GANX Position: Q1 2026 in Review

NewEdge Advisors held its Gain Therapeutics (GANX) position steady in Q1 2026 at 10,600 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

NewEdge Advisors first reported a position in GANX in Q1 2023 and has held it in 9 quarters since. The position peaked at $54.1K in Q1 2023. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

NewEdge Advisors held 10,600 shares of Gain Therapeutics worth $20.6K as of Q1 2026.
NewEdge Advisors left its Gain Therapeutics share count unchanged in Q1 2026.
Gain Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3189 holding.
NewEdge Advisors first reported a position in Gain Therapeutics in Q1 2023 and has held it in 9 quarters since.
NewEdge Advisors's Gain Therapeutics position peaked at $54.1K in Q1 2023.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.